ANKRD62

Across TCGA pan-cancer cohorts, ANKRD62 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ANKRD62 data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher ANKRD62 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD62 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CHOL, UCEC, and LIHC are the cancer types where ANKRD62 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.024	0.728	<.001	36	view →
UCEC	OS	Median	II,III,IV	0.941	0.458	.018	26	view →
LIHC	OS	Median	All	0.083	0.783	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ANKRD62–CHOL (OS)

Open the CHOL breakdown →